Ranbaxy to get royalty for Cipro XR sales in US

Tuesday, 17 December 2002, 08:00 Hrs
Printer Print Email Email
NEW DELHI: India's pharma major Ranbaxy Laboratories Monday said it would be receiving royalty from Bayer for marketing its urinary tract infection drug Cipro XR (Ciprofloxacin extended release tablets), which has been cleared by the U.S. Food and Drug Administration.

Cipro XR, to be marketed in a dosage strength of 500 mg, is administered once a day for three days to treat uncomplicated urinary tract infections (UTIs).

Cipro XR releases the active ingredient from two layers. The first releases ciprofloxacin into the blood within hours. This is followed by a second extended release of the active ingredient to allow sustained levels over 24 hours.

Bayer had submitted the product for FDA approval for marketing in October 2002. It will begin shipping the products to U.S. pharmacies from January 2.
Source: IANS
Ola raises Rs 400 cr for electric
Leading ride-hailing cab aggregator Ola on Friday said it raised Rs 400 crore from its early in..
SpiceJet plans aggressive
Budget passenger carrier SpiceJet plans to aggressively expand its international networks to fl..
GST rate cut to spur Bengaluru
The realty market in India's tech hub is set to grow as lower Goods and Services Tax (GST) rate..
Fossil Group sells smartwatch
Global watch and accessories maker Fossil Group has announced to sell its smartphone technolog..